Statins Improve Survival in Patients With Cardioembolic Stroke
BACKGROUND AND PURPOSE—The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke. METHODS—In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Pa...
Gespeichert in:
| Veröffentlicht in: | Stroke (1970) 2014-06, Vol.45 (6), p.1849-1852 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1852 |
|---|---|
| container_issue | 6 |
| container_start_page | 1849 |
| container_title | Stroke (1970) |
| container_volume | 45 |
| creator | Choi, Jeong-Yoon Seo, Woo-Keun Kang, Sung Hoon Jung, Jin-Man Cho, Kyung-Hee Yu, Sungwook Oh, Kyungmi |
| description | BACKGROUND AND PURPOSE—The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke.
METHODS—In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Patients were classified into nonstatin, low-potency statin, and high-potency statin groups. The primary outcomes were time to mortality and time to recurrent stroke.
RESULTS—The mean duration of follow-up was 22.2 months. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. Statin therapy was independently associated with reduced mortality (hazard ratio, 0.237; 95% confidence interval, 0.080–0.703 for nonstatin versus low-potency statin; hazard ratio, 0.158; 95% confidence interval, 0.037–0.686 for nonstatin versus high-potency statin). Statin treatment did not affect the incidence of recurrent stroke in patients with cardioembolic stroke.
CONCLUSIONS—Statin therapy could be associated with reduced mortality in patients with cardioembolic stroke. |
| doi_str_mv | 10.1161/STROKEAHA.114.005518 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1546220057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1546220057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4284-a520b2c1b28f22642ca7cdcd710b2900ab771df0a5b609e7f7c50205d53d00ca3</originalsourceid><addsrcrecordid>eNpFkFFLwzAUhYMobk7_gUhfBF86b9KkaV-EMaYbDiZ24mNJ05RF01aTdsN_b2RTH0I4uefek_shdIlhjHGMb7P18-pxNplPvKRjAMZwcoSGmBEa0pgkx2gIEKUhoWk6QGfOvQEAiRJ2igaEJhCxlA7RXdaJTjcuWNQftt2qIOvtVm-FCXQTPPmSajoXvOpuE0yFLXWr6qI1WgZZZ9t3dY5OKmGcujjcI_RyP1tP5-Fy9bCYTpahpCShoWAECiJxQZKKkJgSKbgsZcmxf04BRME5LisQrIghVbzikgEBVrKoBJAiGqGb_Vz_yc9euS6vtZPKGNGotnc5Zn5l4iFwb6V7q7Stc1ZV-YfVtbBfOYb8h1z-R85Lmu_J-barQ0Jf1Kr8a_pF5Q3XB4NwUpjKikZq9-9LGCeMwX_-rjWdsu7d9Dtl840Sptv4NAAecwgJYAqxV6E_lEbf4qyFug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546220057</pqid></control><display><type>article</type><title>Statins Improve Survival in Patients With Cardioembolic Stroke</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Choi, Jeong-Yoon ; Seo, Woo-Keun ; Kang, Sung Hoon ; Jung, Jin-Man ; Cho, Kyung-Hee ; Yu, Sungwook ; Oh, Kyungmi</creator><creatorcontrib>Choi, Jeong-Yoon ; Seo, Woo-Keun ; Kang, Sung Hoon ; Jung, Jin-Man ; Cho, Kyung-Hee ; Yu, Sungwook ; Oh, Kyungmi</creatorcontrib><description>BACKGROUND AND PURPOSE—The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke.
METHODS—In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Patients were classified into nonstatin, low-potency statin, and high-potency statin groups. The primary outcomes were time to mortality and time to recurrent stroke.
RESULTS—The mean duration of follow-up was 22.2 months. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. Statin therapy was independently associated with reduced mortality (hazard ratio, 0.237; 95% confidence interval, 0.080–0.703 for nonstatin versus low-potency statin; hazard ratio, 0.158; 95% confidence interval, 0.037–0.686 for nonstatin versus high-potency statin). Statin treatment did not affect the incidence of recurrent stroke in patients with cardioembolic stroke.
CONCLUSIONS—Statin therapy could be associated with reduced mortality in patients with cardioembolic stroke.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.114.005518</identifier><identifier>PMID: 24803594</identifier><identifier>CODEN: SJCCA7</identifier><language>eng</language><publisher>Hagerstown, MD: American Heart Association, Inc</publisher><subject>Biological and medical sciences ; Disease-Free Survival ; Female ; Follow-Up Studies ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Intracranial Embolism - drug therapy ; Intracranial Embolism - mortality ; Male ; Medical sciences ; Nervous system (semeiology, syndromes) ; Neurology ; Retrospective Studies ; Stroke - drug therapy ; Stroke - mortality ; Survival Rate ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Stroke (1970), 2014-06, Vol.45 (6), p.1849-1852</ispartof><rights>2014 American Heart Association, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4284-a520b2c1b28f22642ca7cdcd710b2900ab771df0a5b609e7f7c50205d53d00ca3</citedby><cites>FETCH-LOGICAL-c4284-a520b2c1b28f22642ca7cdcd710b2900ab771df0a5b609e7f7c50205d53d00ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28572550$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24803594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Jeong-Yoon</creatorcontrib><creatorcontrib>Seo, Woo-Keun</creatorcontrib><creatorcontrib>Kang, Sung Hoon</creatorcontrib><creatorcontrib>Jung, Jin-Man</creatorcontrib><creatorcontrib>Cho, Kyung-Hee</creatorcontrib><creatorcontrib>Yu, Sungwook</creatorcontrib><creatorcontrib>Oh, Kyungmi</creatorcontrib><title>Statins Improve Survival in Patients With Cardioembolic Stroke</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>BACKGROUND AND PURPOSE—The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke.
METHODS—In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Patients were classified into nonstatin, low-potency statin, and high-potency statin groups. The primary outcomes were time to mortality and time to recurrent stroke.
RESULTS—The mean duration of follow-up was 22.2 months. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. Statin therapy was independently associated with reduced mortality (hazard ratio, 0.237; 95% confidence interval, 0.080–0.703 for nonstatin versus low-potency statin; hazard ratio, 0.158; 95% confidence interval, 0.037–0.686 for nonstatin versus high-potency statin). Statin treatment did not affect the incidence of recurrent stroke in patients with cardioembolic stroke.
CONCLUSIONS—Statin therapy could be associated with reduced mortality in patients with cardioembolic stroke.</description><subject>Biological and medical sciences</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Intracranial Embolism - drug therapy</subject><subject>Intracranial Embolism - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Retrospective Studies</subject><subject>Stroke - drug therapy</subject><subject>Stroke - mortality</subject><subject>Survival Rate</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkFFLwzAUhYMobk7_gUhfBF86b9KkaV-EMaYbDiZ24mNJ05RF01aTdsN_b2RTH0I4uefek_shdIlhjHGMb7P18-pxNplPvKRjAMZwcoSGmBEa0pgkx2gIEKUhoWk6QGfOvQEAiRJ2igaEJhCxlA7RXdaJTjcuWNQftt2qIOvtVm-FCXQTPPmSajoXvOpuE0yFLXWr6qI1WgZZZ9t3dY5OKmGcujjcI_RyP1tP5-Fy9bCYTpahpCShoWAECiJxQZKKkJgSKbgsZcmxf04BRME5LisQrIghVbzikgEBVrKoBJAiGqGb_Vz_yc9euS6vtZPKGNGotnc5Zn5l4iFwb6V7q7Stc1ZV-YfVtbBfOYb8h1z-R85Lmu_J-barQ0Jf1Kr8a_pF5Q3XB4NwUpjKikZq9-9LGCeMwX_-rjWdsu7d9Dtl840Sptv4NAAecwgJYAqxV6E_lEbf4qyFug</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Choi, Jeong-Yoon</creator><creator>Seo, Woo-Keun</creator><creator>Kang, Sung Hoon</creator><creator>Jung, Jin-Man</creator><creator>Cho, Kyung-Hee</creator><creator>Yu, Sungwook</creator><creator>Oh, Kyungmi</creator><general>American Heart Association, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201406</creationdate><title>Statins Improve Survival in Patients With Cardioembolic Stroke</title><author>Choi, Jeong-Yoon ; Seo, Woo-Keun ; Kang, Sung Hoon ; Jung, Jin-Man ; Cho, Kyung-Hee ; Yu, Sungwook ; Oh, Kyungmi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4284-a520b2c1b28f22642ca7cdcd710b2900ab771df0a5b609e7f7c50205d53d00ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biological and medical sciences</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Intracranial Embolism - drug therapy</topic><topic>Intracranial Embolism - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Retrospective Studies</topic><topic>Stroke - drug therapy</topic><topic>Stroke - mortality</topic><topic>Survival Rate</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Jeong-Yoon</creatorcontrib><creatorcontrib>Seo, Woo-Keun</creatorcontrib><creatorcontrib>Kang, Sung Hoon</creatorcontrib><creatorcontrib>Jung, Jin-Man</creatorcontrib><creatorcontrib>Cho, Kyung-Hee</creatorcontrib><creatorcontrib>Yu, Sungwook</creatorcontrib><creatorcontrib>Oh, Kyungmi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Jeong-Yoon</au><au>Seo, Woo-Keun</au><au>Kang, Sung Hoon</au><au>Jung, Jin-Man</au><au>Cho, Kyung-Hee</au><au>Yu, Sungwook</au><au>Oh, Kyungmi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins Improve Survival in Patients With Cardioembolic Stroke</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2014-06</date><risdate>2014</risdate><volume>45</volume><issue>6</issue><spage>1849</spage><epage>1852</epage><pages>1849-1852</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><coden>SJCCA7</coden><abstract>BACKGROUND AND PURPOSE—The objective of this study was to investigate the potential benefits of statin therapy on mortality and stroke recurrence after cardioembolic stroke.
METHODS—In this retrospective observational study, we analyzed data from 535 patients with first-ever cardioembolic stroke. Patients were classified into nonstatin, low-potency statin, and high-potency statin groups. The primary outcomes were time to mortality and time to recurrent stroke.
RESULTS—The mean duration of follow-up was 22.2 months. The cumulative mortality rate was 7% at the end of the first year and 10% at the end of the third year. Statin therapy was independently associated with reduced mortality (hazard ratio, 0.237; 95% confidence interval, 0.080–0.703 for nonstatin versus low-potency statin; hazard ratio, 0.158; 95% confidence interval, 0.037–0.686 for nonstatin versus high-potency statin). Statin treatment did not affect the incidence of recurrent stroke in patients with cardioembolic stroke.
CONCLUSIONS—Statin therapy could be associated with reduced mortality in patients with cardioembolic stroke.</abstract><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>24803594</pmid><doi>10.1161/STROKEAHA.114.005518</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0039-2499 |
| ispartof | Stroke (1970), 2014-06, Vol.45 (6), p.1849-1852 |
| issn | 0039-2499 1524-4628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1546220057 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Biological and medical sciences Disease-Free Survival Female Follow-Up Studies Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Intracranial Embolism - drug therapy Intracranial Embolism - mortality Male Medical sciences Nervous system (semeiology, syndromes) Neurology Retrospective Studies Stroke - drug therapy Stroke - mortality Survival Rate Vascular diseases and vascular malformations of the nervous system |
| title | Statins Improve Survival in Patients With Cardioembolic Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T13%3A04%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins%20Improve%20Survival%20in%20Patients%20With%20Cardioembolic%20Stroke&rft.jtitle=Stroke%20(1970)&rft.au=Choi,%20Jeong-Yoon&rft.date=2014-06&rft.volume=45&rft.issue=6&rft.spage=1849&rft.epage=1852&rft.pages=1849-1852&rft.issn=0039-2499&rft.eissn=1524-4628&rft.coden=SJCCA7&rft_id=info:doi/10.1161/STROKEAHA.114.005518&rft_dat=%3Cproquest_cross%3E1546220057%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1546220057&rft_id=info:pmid/24803594&rfr_iscdi=true |